Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM)

Charles Schwab Investment Management Inc. increased its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 3.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 457,252 shares of the company’s stock after buying an additional 14,775 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Immunome were worth $4,856,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC purchased a new stake in shares of Immunome during the third quarter worth about $219,000. Cerity Partners LLC increased its holdings in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after purchasing an additional 5,043 shares during the last quarter. FMR LLC increased its stake in shares of Immunome by 0.3% in the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after acquiring an additional 13,757 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Immunome by 129.1% in the third quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock valued at $442,000 after purchasing an additional 17,053 shares during the period. Finally, Janus Henderson Group PLC increased its position in Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IMNM has been the subject of several analyst reports. Stephens reissued an “overweight” rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Guggenheim decreased their price target on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome presently has an average rating of “Buy” and a consensus price target of $25.50.

Immunome Stock Performance

Immunome stock opened at $6.95 on Wednesday. Immunome, Inc. has a fifty-two week low of $6.94 and a fifty-two week high of $26.70. The firm has a 50 day moving average price of $9.67 and a 200 day moving average price of $11.44. The company has a market capitalization of $604.31 million, a PE ratio of -0.86 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Insider Activity

In related news, CEO Clay B. Siegall acquired 150,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The shares were bought at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares in the company, valued at $193,879.15. This represents a 42.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 169,300 shares of company stock worth $1,323,536. Corporate insiders own 8.60% of the company’s stock.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.